ADGRE3

Across TCGA pan-cancer cohorts, ADGRE3 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ADGRE3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ADGRE3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ADGRE3 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where ADGRE3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADGRE3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.712	<.001	8	view →
LUAD	Female	II,III,IV	−0.853	<.001	6	view →
LSCC	Male	All	−0.548	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

ADGRE3–HNSC

Open the HNSC breakdown →